Monsanto Company

Midatech Limited

Rodaris Pharmaceuticals Limited

Monosol Rx, LLC

Rademacher Group Limited

Other

Consejo Superior De Investigaciones Cientificas

Middlesex University Higher Education Corporation

Sylus Pharmaceuticals Ltd.

G.d. Searle & Company

Aquestive Therapeutics, Inc.

Thomas William Rademacher

Raymond A Dwek

Phillip Williams

Hugo Norberto Caro

Manuel Martin-Lomas

Irene Francois

George W Fleet

Raj B Parekh

Raymond Allen Dwek

Joseph Feder

Gary S Jacob

Alexander Mark Schobel

Graham A Rook

Christopher W Redman

Patricia McLean

Peter D Arkwright

William R Tolbert

Eric Dadey

Soledad Penades Ullate

Africa Garcia Barrientos

Rafael Ojeda Martinez De Castilla

Peter R Scudder

Simon Wong

Ian D Manger

George William Fleet

Garry L Myers

Gottfried Himmler

Susan C Howard

Arthur J Wittwer

Ivan Maurice Roitt

A Stanley Tyms

Jan Mous

Soledad Penades

Ralf Kircheis

Philip Williams

Esther De Torres Dominguez

Keith Joseph Kendall

Andreas Demosthenous

Leslie Greenbaum

Manuel Martin Lomas

Jose Luis De Paz Carrera

Africa Garcia Barrientes

Christopher J Edge

Mark R Wormald

Godfrey Bradman

Justin N W Barry

David K Male

Raymond Kruse Iles

Christof Bachmann

Javier Del Campo Menoyo

Richard Harold Bayford

Jesus Martines De La Fuente

G C Mudde

Ester De Torres Dominguez

Khalid Gumaa

Africa Barrientos

Rafael Ojeda

M Martin-Lomas

J Martines De La Fuente

S Penades

M Cons Sup De Investigac Cient Martin-Lomas

J Cons De Inv Cient Martines De La Fuente

S Consejo Sup De Investigaciones Cient Penades

Frank Charles Hay

Katherine Birgitta Bodman

Justin Nw Barry

Geert C Mudde

Ester De Dominguez

Javier Del Menoyo

Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise a carbohydrate, insulin and/or a glutathione; and (b) the at least one agent to be delivered to the CNS. Methods of treatment and diagnosing CNS disorders utilizing the nanoparticle delivery systems and related screening methods are also disclosed.

Nanoparticle delivery compositions

The present invention provides nanoparticles and compositions comprising such nanoparticles, as well as methods for intracellular delivery of peptides, and methods of producing nanoparticles and related products. The nanoparticles comprise a core comprising a metal and/or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that is covalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises a peptide of choice that is covalently linked to the core via a second linker. The second linker comprises a peptide portion and a non-peptide portion, wherein said peptide portion of said second linker comprises the sequence XXZ, wherein: Xis an amino acid selected from A and G; Xis an amino acid selected from A and G; and Zis an amino acid selected from Y and F.

Nanoparticle-peptide compositions

Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.

Combination peptide-nanoparticles and delivery systems incorporating same

The present invention relates to insulin- and insulin analog-carrying nanoparticles formulated together with or for use with free insulin or with an insulin analog, such as a rapidly-acting insulin analog. The compositions of the present invention find use in medicine, particularly in glycemic control, e.g. for controlling blood glucose levels in diabetic subjects. Nanoparticle compositions of the invention, formulated together with or for use with free insulin or with an insulin analog, comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprise at least one carbohydrate moiety; and at least one insulin peptide and/or insulin analog peptide that is non-covalently bound to the corona.

Nanoparticle-insulin and insulin analogue compositions

The use of nanoparticles for imaging a tumor in a mammal using electrical impedance tomography. The nanoparticles comprise a core of metal and/or semiconductor atoms to which are linked ligands that comprise a molecule capable of attaching to a specific tumor biomarker.

Detection of cancer with electrical impedance tomography

The present invention relates to amylin peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of blood glucose regulation. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise glutathione; and at least one amylin peptide that is non-covalently bound to the corona.

Nanoparticle peptide compositions

Nanoparticles comprising adjuvants and antigens, such as tumor and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.

Nanoparticles comprising antigens and adjuvants, and immunogenic structures

Materials and Methods are disclosed for producing nanoparticles linked to antibacterial ligands, including antibiotics and/or molecules which bind to bacterial markers, and for the use of the nanoparticles for the treatment of conditions treatable by the antibiotic ligands.

Nanoparticles comprising antibacterial ligands

A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.

Nanoparticle film delivery systems

Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent.

Nanoparticles for providing immune responses against infectious agents

Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein peptides are bound to or associated with the nanoparticles.

Peptide-carrying nanoparticles

Materials and methods for making small magnetic particles, e.g. clusters of metal atoms, which can be employed as a substrate for immobilizing a plurality of ligands. Also disclosed are uses of these magnetic nanoparticles as therapeutic and diagnostic reagents, and in the study of ligand-mediated interactions.

Magnetic nanoparticles

Compounds having a mimetic or antagonistic property of an inositol phosphoglycan, and the uses of these compounds are disclosed, together with the use, e.g. to treat a condition ameliorated by administration of an IPG second messenger or an IPG antagonist thereof. In particular, the compounds are based on the 1,6 linkage of a sugar residue and a cyclitol.

Compounds and their uses

Growing community of inventors

Oxford, United Kingdom

Thomas William Rademacher